TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2785470

Group type: EXPERIMENTAL
Intervention: Esophageal varices developed in patients with primary biliary cirrhosis
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Esophageal variceal bleeding in patients with esophageal varices
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Time to development of esophageal varices
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: 1- and 3-year survival estimates after development of esophageal varices
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: 1- and 3-year survival estimates after initial variceal bleeding episode
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Development of esophageal varices
Number of subjects: 265
Study: 1099642

Group type: EXPERIMENTAL
Intervention: Chymoral
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 30870403

Group type: EXPERIMENTAL
Intervention: Glucocorticoid combined with ursodeoxycholic acid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ursodeoxycholic acid
Number of subjects: 60
Study: 28902739

Group type: EXPERIMENTAL
Intervention: HD+i-Scan colonoscopy
Number of subjects: 449

Group type: COMPARATOR
Intervention: HD colonoscopy
Number of subjects: 449
Study: 25939016

Group type: EXPERIMENTAL
Intervention: Guided self-help
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Unguided self-help
Number of subjects: 150

Group type: COMPARATOR
Intervention: Guided self-help and Unguided self-help
Number of subjects: 150
Study: 23650416

Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg daily plus entinostat 5 mg once per week (EE)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Exemestane plus placebo (EP)
Number of subjects: 130
Study: 21741642

Group type: EXPERIMENTAL
Intervention: HD‐WLE or pCLE
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: HD‐WLE, NBI, or pCLE
Number of subjects: 101

Group type: COMPARATOR
Intervention: HD‐WLE
Number of subjects: 101

Group type: COMPARATOR
Intervention: HD‐WLE or NBI
Number of subjects: 101
Study: 19359813

Group type: EXPERIMENTAL
Intervention: 100 mg/day of bepridil
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 200 mg/day of bepridil
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 16959427

Group type: EXPERIMENTAL
Intervention: Self-hypnotic relaxation
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Structured empathic attention
Number of subjects: 236

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 236
Study: 15858257

Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 11062381

Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy (NHT) using an LHRH analog (goserelin) plus flutamide for a period of 3 months
Number of subjects: 402

Group type: COMPARATOR
Intervention: Radical prostatectomy (RP) only
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy (NHT)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Radical prostatectomy (RP)
Number of subjects: 402
Study: 9066598

Group type: EXPERIMENTAL
Intervention: EPI alone (120 mg/m2 x 3)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: EPI + ICRF‐187 (1000 mg/m2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: EPI + C0Q10 (50 mg/day)
Number of subjects: 30
Study: 8373608

Group type: EXPERIMENTAL
Intervention: Laryngeal indices caliper measurement
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Thiopental sodium (4 mg/kg) and succinylcholine (1 mg/kg)
Number of subjects: 101
Study: 31812946

Group type: EXPERIMENTAL
Intervention: Jump rope exercise program (EX)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 48
Study: 30892373

Group type: EXPERIMENTAL
Intervention: Intracanal laser application
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (mock laser application)
Number of subjects: 39
Study: 28230639

Group type: EXPERIMENTAL
Intervention: Everolimus with reduced tacrolimus starting at 1 month post-transplant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early discontinuation of CNI therapy after introduction of an mTOR inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mTOR inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mTOR inhibitor initiation in maintenance patients
Number of subjects: 0
Study: 25397922

Group type: EXPERIMENTAL
Intervention: Participants with low levels of FNE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants with high levels of FNE
Number of subjects: 0
Study: 23578724

Group type: EXPERIMENTAL
Intervention: Mitomycin (12 mg/m² on day 1) with fluorouracil (1000 mg/m² per day on days 1-4 and 29-32) and radiotherapy (50.4 Gy in 28 daily fractions)
Number of subjects: 940

Group type: COMPARATOR
Intervention: Cisplatin (60 mg/m² on days 1 and 29) with fluorouracil (1000 mg/m² per day on days 1-4 and 29-32) and radiotherapy (50.4 Gy in 28 daily fractions)
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy (fluorouracil and cisplatin at weeks 11 and 14)
Number of subjects: 940

Group type: COMPARATOR
Intervention: No maintenance chemotherapy
Number of subjects: 940
Study: 21205602

Group type: EXPERIMENTAL
Intervention: Primary PCI performed by six experienced interventional cardiologists
Number of subjects: 1071

Group type: COMPARATOR
Intervention: Primary PCI
Number of subjects: 1071
Study: 19707010

Group type: EXPERIMENTAL
Intervention: 10% hydrogen peroxide whitening strips (Crest Whitestrips Premium)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo strips without peroxide
Number of subjects: 42
Study: 17264222

Group type: EXPERIMENTAL
Intervention: HD+AA (2 h of hemodialysis with amino acid infusion)
Number of subjects: 8

Group type: COMPARATOR
Intervention: HD-O (2 h of hemodialysis without amino acid infusion)
Number of subjects: 8
Study: 15989744

Group type: EXPERIMENTAL
Intervention: 2.ED95 R plus 1.ED95 M (2R1M)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 2.ED95 R plus 2.ED95 M (2R2M)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 2.ED95 R alone (2R)
Number of subjects: 45
Study: 11560566

Group type: EXPERIMENTAL
Intervention: Clozapine (50 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Haloperidol (3 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9713556

Group type: EXPERIMENTAL
Intervention: Tibolone (TIB) 2.5 mg/day (n = 28)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral oestradiol 2 mg/day (PO) plus sequential dydrogesterone 10 mg/day for 14 of 28 days per cycle (n = 26)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol patch (TTS) releasing 50 micrograms/day plus oral sequential dydrogesterone 10 mg/day for 14 of 28 days per cycle (n = 20)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (n = 26)
Number of subjects: 100
Study: 7821833

Group type: EXPERIMENTAL
Intervention: Clindamycin + Gentamicin
Number of subjects: 65

Group type: COMPARATOR
Intervention: Penicillin + Chloramphenicol + Gentamicin
Number of subjects: 65
Study: 3139728

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium Cromoglycate (SCG)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 10
Study: 29683704

Group type: EXPERIMENTAL
Intervention: Nicotine e‐cigarettes
Number of subjects: 128

Group type: COMPARATOR
Intervention: Instructional set (told nicotine)
Number of subjects: 128
Study: 26016697

Group type: EXPERIMENTAL
Intervention: Digital cognitive behavioural therapy (CBT) for insomnia (in addition to treatment as usual)
Number of subjects: 2614

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Digital cognitive behavioural therapy (CBT) for insomnia
Number of subjects: 2614
Study: 23032417

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (TIV), two doses 1 month apart
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 410
Study: 20919540

Group type: EXPERIMENTAL
Intervention: Infusion therapy based on routine hemodynamic parameters (blood pressure, heart rate, central venous pressure, daily fluid balance)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nontraumatic intracranial hemorrhages
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Severe brain injury
Number of subjects: 45
Study: 18431264

Group type: EXPERIMENTAL
Intervention: hANP (0.01‐0.05 microg/kg/min)
Number of subjects: 40
Study: 17075113

Group type: EXPERIMENTAL
Intervention: Ovarian ablation by irradiation
Number of subjects: 762

Group type: COMPARATOR
Intervention: Chemotherapy with intravenous cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 762
Study: 14594437

Group type: EXPERIMENTAL
Intervention: Epoetin-alfa
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 11200917

Group type: EXPERIMENTAL
Intervention: Septic shock patients
Number of subjects: 25
Study: 9005122

Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg before breakfast)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Ranitidine (300 mg before bedtime)
Number of subjects: 95
Study: 1377118

Group type: EXPERIMENTAL
Intervention: Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF)
Number of subjects: 0
Study: 3977145

Group type: EXPERIMENTAL
Intervention: Military antishock trousers (MAST)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no MAST)
Number of subjects: 68
Study: 31005969

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU monthly)
Number of subjects: 5110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5110
Study: 28936962

Group type: EXPERIMENTAL
Intervention: New type of tracheal catheter fixation tape
Number of subjects: 90

Group type: COMPARATOR
Intervention: Traditional medical adhesive tape and fixation belt
Number of subjects: 90
Study: 26297722

Group type: EXPERIMENTAL
Intervention: Compulsory vaccination intervention (n = 144)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Voluntary vaccination control group (n = 153)
Number of subjects: 297
Study: 25129485

Group type: EXPERIMENTAL
Intervention: Peri-Strips Dry® with Veritas® (PSD-V)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no buttress material)
Number of subjects: 100
Study: 22491410

Group type: EXPERIMENTAL
Intervention: Patching therapy (1 hour per day per month of age until 8 months, then 50% of waking hours thereafter)
Number of subjects: 108
Study: 19449344

Group type: EXPERIMENTAL
Intervention: Danshen dripping pill (DDP)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Non-DDP treatment (Control)
Number of subjects: 106
Study: 17942272

Group type: EXPERIMENTAL
Intervention: Redesigned advance directive (fifth grade reading level with graphics)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Redesigned advance directive
Number of subjects: 205

Group type: COMPARATOR
Intervention: Standard advance directive (>12th grade level)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Standard advance directive
Number of subjects: 205
Study: 15388301

Group type: EXPERIMENTAL
Intervention: 5-year-olds in Experiment 1 when the sought entity was a person
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 5-year-olds in Experiment 1 when the sought entity was a physical object
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 5-year-olds in Experiment 2 when asked where the searching protagonist would look first
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 5-year-olds in Experiment 2 when asked what the protagonist would do next
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 5-year-olds in Experiment 2 with the word 'first' in the question
Number of subjects: 153
Study: 11208681

Group type: EXPERIMENTAL
Intervention: losartan (25 mg/d)
Number of subjects: 141

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 141
Study: 9413448

Group type: EXPERIMENTAL
Intervention: Isometric muscle contractions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Eccentric muscle contractions
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 8500862

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 3628831

Group type: EXPERIMENTAL
Intervention: Apomorphine HCl (0.25, 0.5, 0.75, 1.0 mg sc)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5-3.75 mg/d po)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29587666

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pemetrexed-cisplatin
Number of subjects: 0
Study: 27574998

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (≥60 seconds)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Immediate cord clamping (<10 seconds)
Number of subjects: 266
Study: 23805799

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors
Number of subjects: 180
Study: 22074912

Group type: EXPERIMENTAL
Intervention: Pictographs (shaded blocks)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pictographs (unshaded dots)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bar charts (medium numerators)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pictographs (small numerators)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bar charts (medium/large numerators)
Number of subjects: 120
Study: 20679835

Group type: EXPERIMENTAL
Intervention: Topical silicone gel
Number of subjects: 23
Study: 18639628

Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-relaxation
Number of subjects: 36
Study: 15883488

Group type: EXPERIMENTAL
Intervention: 0.05% mequitazine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.05% levocabastine
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.1% dexamethasone
Number of subjects: 24
Study: 12520633

Group type: EXPERIMENTAL
Intervention: Gatifloxacin with calcium-fortified orange juice
Number of subjects: 16

Group type: COMPARATOR
Intervention: Gatifloxacin with water
Number of subjects: 16

Group type: COMPARATOR
Intervention: Gatifloxacin with nonfortified orange juice
Number of subjects: 16
Study: 10760725

Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate (OC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 42
Study: 8770475

Group type: EXPERIMENTAL
Intervention: Automated, unedited analyses of phantom images
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Clinical image analysis using differing QCA systems
Number of subjects: 11
Study: 1300301

Group type: EXPERIMENTAL
Intervention: 0.03% Flurbiprofen‐Na+ eye drops 1/2 hourly starting two hours before surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no flurbiprofen)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.03% Flurbiprofen‐Na+ eye drops
Number of subjects: 50
Study: 6543134

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (100-200 mg/day for 7-14 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Stage-matched control group
Number of subjects: 11
Study: 31622058

Group type: EXPERIMENTAL
Intervention: Allokin-alpha therapy (9 injections of s/c, 1.0 mg every other day)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Valtrex (500 mg x 2 times/day, by mouth for two months)
Number of subjects: 59
Study: 31168175

Group type: EXPERIMENTAL
Intervention: Allogeneic platelet gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hydrogel
Number of subjects: 60
Study: 26317300

Group type: EXPERIMENTAL
Intervention: Increased workloads (0.5, 1, 1.5, 2, and 2.5 kg at 60 rpm)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Increased cadences (70, 80, and 90 rpm with 1-kg workload)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Increased workloads at constant cadence
Number of subjects: 18
Study: 24274958

Group type: EXPERIMENTAL
Intervention: Delaire-type facemask (FM)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Modified tandem traction bow appliance (MTTBA)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (observed without treatment)
Number of subjects: 65
Study: 22709731

Group type: EXPERIMENTAL
Intervention: Training professionals in assisted living facilities (two half-day sessions)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Usual care procedures and delayed training (control group)
Number of subjects: 212
Study: 20160081

Group type: EXPERIMENTAL
Intervention: Oxytocin inhalation
Number of subjects: 13
Study: 18072057

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 100
Study: 16238894

Group type: EXPERIMENTAL
Intervention: GAL-ER 24 mg qd (fasted)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: GAL-ER 24 mg qd (fed)
Number of subjects: 24

Group type: COMPARATOR
Intervention: GAL-IR 12 mg bid (fasted)
Number of subjects: 24
Study: 12387474

Group type: EXPERIMENTAL
Intervention: Suture closure (3‐0 Dexon II)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Adhesive strip closure (Steri‐Strip)
Number of subjects: 250
Study: 10628237

Group type: EXPERIMENTAL
Intervention: Family life education program (abstinence-based adolescent pregnancy prevention program)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Delayed treatment condition (control)
Number of subjects: 251
Study: 7769096

Group type: EXPERIMENTAL
Intervention: Vanadyl sulfate (VS) 100 mg/d for 3 weeks
Number of subjects: 6
Study: 2311809

Group type: EXPERIMENTAL
Intervention: 20 mg intramuscular bromocriptine retard
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 30 mg intramuscular bromocriptine retard
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 40 mg intramuscular bromocriptine retard
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 50 mg intramuscular bromocriptine retard
Number of subjects: 108
Study: 6810298

Group type: EXPERIMENTAL
Intervention: Pacifier for nonnutritive sucking during tube feedings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group infants (no pacifier)
Number of subjects: 0
Study: 31795482

Group type: EXPERIMENTAL
Intervention: AAT-120 (60 or 120 mg/kg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: AAT-60 (60 or 120 mg/kg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: AAT-60
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: AAT-120
Number of subjects: 70
Study: 29779416

Group type: EXPERIMENTAL
Intervention: Indacaterol/Glycopyrronium (110/50 μg once daily)
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Triple Therapy (tiotropium [18 μg] once daily plus salmeterol/fluticasone propionate [50/500 μg] twice daily)
Number of subjects: 1053
Study: 26681262

Group type: EXPERIMENTAL
Intervention: Oxytocin treatment spray (placebo)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Serotonin treatment spray (placebo)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 77
Study: 24991714

Group type: EXPERIMENTAL
Intervention: Ventral surgery
Number of subjects: 250

Group type: COMPARATOR
Intervention: Dorsal surgery (laminectomy/fusion or laminoplasty)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Postoperative sagittal balance
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Health resource use for ventral procedures
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Overall health-related quality of life
Number of subjects: 250
Study: 22293126

Group type: EXPERIMENTAL
Intervention: Uridine (NucleomaxX(®); Pharma Nord)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tenofovir (TDF) switch
Number of subjects: 50
Study: 19159693

Group type: EXPERIMENTAL
Intervention: Nicotine (12 microg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 24
Study: 17234506

Group type: EXPERIMENTAL
Intervention: Formulation containing 460 mg of omega-3 polyunsaturated fatty acids and/or 580 mg of soluble fibers
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 16847182

Group type: EXPERIMENTAL
Intervention: Nasal treatment with amphotericin B for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline control for 8 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Successful fungus eradication
Number of subjects: 60
Study: 14676082

Group type: EXPERIMENTAL
Intervention: Etanercept, 25 mg, subcutaneously twice a week for 24 weeks
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 112

Group type: COMPARATOR
Intervention: Etanercept and Placebo
Number of subjects: 112
Study: 11030848

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion of 40 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 30
Study: 8796393

Group type: EXPERIMENTAL
Intervention: 5 mg of i.v. nicardipine
Number of subjects: 8
Study: 1339758

Group type: EXPERIMENTAL
Intervention: Leponex (clozapine)
Number of subjects: 1062
Study: 6722081

Group type: EXPERIMENTAL
Intervention: Nutrient-dense supplement (A)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo (B)
Number of subjects: 225
Study: 29763373

Group type: EXPERIMENTAL
Intervention: Oral glucose challenge (OGC, 50 g glucose)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Mixed-meal challenge (MMC)
Number of subjects: 15
Study: 27956074

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - 15 weekly group sessions based on a CBT manual, commenced immediately after discharge.
Number of subjects: 155

Group type: COMPARATOR
Intervention: Usual care during a 4-month waiting list interval.
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - 15 weekly group sessions based on a CBT manual.
Number of subjects: 155
Study: 25480457

Group type: EXPERIMENTAL
Intervention: Presentation of prognostic data as frequencies (e.g., 1 in 50)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Framing qualitative data in terms of chance of death
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Framing quantitative data in terms of chance of death
Number of subjects: 141